Former BioD investors are looking for an accelerated $26.5 million earnout after ex-CEO Russell Olsen resigned from Integra Lifesciences (NSDQ:IART). BioD merged with Derma Sciences for $80 million in Aug. 2016., which was later bought by Integra for $200 million. After the series of acquisition, Olsen told Integra that he believed his new job offer materially diminished […]
BioD
Titan Medical loses clinical & regulatory EVP Fowler | Personnel Moves for August 29, 2016
Titan Medical loses clinical & regulatory EVP Fowler Titan Medical (CVE:TMD) said today that its executive vice president for clinical & regulatory affairs, Dr. Dennis Fowler, plans to resign effective August 31. Toronto-based robot-assisted surgery company Titan, which is grappling with the suspension of its product development program, said Fowler’s duties will be divided on an […]
Derma Sciences closes $80m deal for BioD
Derma Sciences (NSDQ:DSCI) said yesterday that it closed its acquisition of regenerative allograft maker BioD in a deal worth up to $78 million, including milestones and earn-outs. Princeton, N.J.-based Derma Sciences said it paid $21.3 million up front in a mix of cash and stock; meeting regulatory milestones could mean another $30 million, and the transaction included $26.5 million in earn-outs […]
Derma Sciences acquires BioD for $21.3m
Derma Sciences (NSDQ:DSCI) said today it is buying regenerative medicine developer BioD for $21.3 million up front, with the possibility of an additional $56.5 million. The deal between Princeton, N.J.-based Derma Sciences and Cordova, Tenn.-based BioD includes regulatory milestone payments up to $30 million and earn outs based on net sales growth of up to $26.5 million. “The acquisition of […]
